KR102828978B1 - 트리파르타이트 모티프 함유 단백질 16(trim16) 신호전달을 유도하기 위한 조성물 및 방법 - Google Patents

트리파르타이트 모티프 함유 단백질 16(trim16) 신호전달을 유도하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102828978B1
KR102828978B1 KR1020207025399A KR20207025399A KR102828978B1 KR 102828978 B1 KR102828978 B1 KR 102828978B1 KR 1020207025399 A KR1020207025399 A KR 1020207025399A KR 20207025399 A KR20207025399 A KR 20207025399A KR 102828978 B1 KR102828978 B1 KR 102828978B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
rna
uuuuuuuuuu
pamp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207025399A
Other languages
English (en)
Korean (ko)
Other versions
KR20200116976A (ko
Inventor
마이클 제이 주니어 게일
Original Assignee
유니버시티 오브 워싱톤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 워싱톤 filed Critical 유니버시티 오브 워싱톤
Publication of KR20200116976A publication Critical patent/KR20200116976A/ko
Application granted granted Critical
Publication of KR102828978B1 publication Critical patent/KR102828978B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207025399A 2018-02-02 2019-02-01 트리파르타이트 모티프 함유 단백질 16(trim16) 신호전달을 유도하기 위한 조성물 및 방법 Active KR102828978B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625623P 2018-02-02 2018-02-02
US62/625,623 2018-02-02
PCT/US2019/016413 WO2019152884A1 (en) 2018-02-02 2019-02-01 Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Publications (2)

Publication Number Publication Date
KR20200116976A KR20200116976A (ko) 2020-10-13
KR102828978B1 true KR102828978B1 (ko) 2025-07-02

Family

ID=67479930

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025399A Active KR102828978B1 (ko) 2018-02-02 2019-02-01 트리파르타이트 모티프 함유 단백질 16(trim16) 신호전달을 유도하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (1) US20210046168A1 (https=)
EP (1) EP3746088B1 (https=)
JP (1) JP7409612B2 (https=)
KR (1) KR102828978B1 (https=)
CN (1) CN111836623A (https=)
AU (1) AU2019215191B2 (https=)
BR (1) BR112020015821A2 (https=)
RU (1) RU2020128838A (https=)
WO (1) WO2019152884A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021067480A1 (en) * 2019-10-02 2021-04-08 University Of Washington Compositions and methods for treatment of hepatitis b virus infection
WO2021097347A1 (en) * 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4112665A4 (en) * 2020-03-27 2024-04-10 Mitsui Chemicals, Inc. LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526778A (ja) 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
US20150017207A1 (en) * 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2016179034A2 (en) * 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526778A (ja) 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
US20150017207A1 (en) * 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology. 2017. Vol.28. No.8, pp.1756-1766.*
Nature. 2008. Vol.454, No.7203, pp.523-527.
Selina K. Sutton. University of New South Wales 박사학위 논문(2014. March).*

Also Published As

Publication number Publication date
EP3746088B1 (en) 2024-07-10
CN111836623A (zh) 2020-10-27
BR112020015821A2 (pt) 2021-03-09
AU2019215191A1 (en) 2020-09-17
JP7409612B2 (ja) 2024-01-09
EP3746088A4 (en) 2023-02-22
EP3746088A1 (en) 2020-12-09
KR20200116976A (ko) 2020-10-13
EP3746088C0 (en) 2024-07-10
WO2019152884A1 (en) 2019-08-08
AU2019215191B2 (en) 2025-08-14
US20210046168A1 (en) 2021-02-18
JP2021512123A (ja) 2021-05-13
RU2020128838A (ru) 2022-03-03

Similar Documents

Publication Publication Date Title
KR102828978B1 (ko) 트리파르타이트 모티프 함유 단백질 16(trim16) 신호전달을 유도하기 위한 조성물 및 방법
Wang et al. The BET family in immunity and disease
Bavelloni et al. AKT‐dependent phosphorylation of the adenosine deaminases ADAR‐1 and‐2 inhibits deaminase activity
AU2020283323A1 (en) Treatment of ALT cancers
CN112996802B (zh) 用于制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
Nandi et al. CD155: a key receptor playing diversified roles
CN109609644B (zh) Pax3-fkhr和acta1基因在预防、治疗横纹肌肉瘤中的用途
WO2017106189A1 (en) Compositions and methods for treating ras/mapk mutant lung cancer
AU2018301504B2 (en) Method for managing pain
US20060052322A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
Li et al. A role for mitogen‐activated protein kinase and Ets‐1 in the induction of interleukin‐10 transcription by human immunodeficiency virus‐1 Tat
WO2013047941A1 (ko) 비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법
JP2004180540A (ja) 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
JP2015515485A (ja) Ｒｎａリガーゼ複合体メンバーとしてのアーキアーゼ
EP3984558A1 (en) Method for inhibiting infection and activation of virus
US10876116B2 (en) Anti-ARID3a treatments for inflammatory disorders
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
WO2020165570A1 (en) Methods relating to disrupting the binding of af9 partner proteins to af9 and/or enl
Hao et al. ZUP1 is a key component of the MAVS complex and acts as a protector of host against viral invasion
CN106319020B (zh) p97基因治疗病毒感染的用途及其相关药物
JPWO2004027061A1 (ja) 抗増殖性疾患治療薬のスクリーニング法
WO2016128744A1 (en) Senescence
JP2005312304A (ja) 新規インターフェロン制御因子活性化ポリペプチド及びそれをコードする核酸
HK40122461A (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
HK40054624B (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200902

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240429

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250425

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250630

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration